Avon
This article was originally published in The Rose Sheet
Executive Summary
Direct-seller raises its earnings guidance for Q2 and full-year 2004 in light of "significant reduction" in firm's effective tax rate, which is expected to fall from 35% to approximately 31%, Avon announces June 8. Firm anticipates Q2 earnings per share will be up 28% to $.46, $.03 higher than previous guidance. Full-year EPS growth is projected to be $1.70 a share, up 22% versus 2003, and $.05 above prior expectations. Second quarter sales are expected to increase 12% in dollars and 11% in local currencies compared to the year-ago period, fueled by an expected 14% increase in beauty sales. Operating profit likely will rise 14% during the quarter, firm adds. U.S. sales are forecast to grow 4% in Q2, driven by 6% growth in beauty sales and 3% increase in the number of active representatives...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.